Phillip G. Febbo insider trades: Veracyte (VCYT) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Phillip reports to the SEC
Open-market buys and sales
16 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | VCYT | ↓ Sell | 13,110 | $43.05 | $564K | Direct | Sep 4, 2026 (0d) |
| Mar 2, 2026 | VCYT | ↓ Sell | 13,425 | $36.16 | $485K | Direct | Mar 4, 2026 (2d) |
| Oct 6, 2025 | VCYT | ↓ Sell | 8,349 | $36.02 | $301K | Direct | Oct 7, 2025 (1d) |
| Mar 4, 2025 | VCYT | ↓ Sell | 8,037 | $33.35 | $268K | Direct | Mar 6, 2025 (2d) |
| Dec 4, 2024 | VCYT | ↓ Sell | 3,934 | $44.09 | $173K | Direct | Dec 6, 2024 (2d) |
| Apr 6, 2022 | ILMN | ↓ Sell10b5-1 | 1,988 | $360.01 | $716K | Direct | Apr 7, 2022 (1d) |
| Nov 8, 2021 | ILMN | ↓ Sell10b5-1 | 1,000 | $406.83 | $407K | Direct | Nov 9, 2021 (1d) |
| Jun 11, 2021 | ILMN | ↓ Sell10b5-1 | 1,000 | $447.59 | $448K | Direct | Jun 14, 2021 (3d) |
| Nov 6, 2020 | ILMN | ↓ Sell10b5-1 | 155 | $310.10 | $48K | Direct | Nov 9, 2020 (3d) |
| Apr 16, 2020 | ILMN | ↓ Sell10b5-1 | 173 | $300.00 | $52K | Direct | Apr 20, 2020 (4d) |
| Nov 14, 2019 | ILMN | ↓ Sell10b5-1 | 155 | $300.00 | $47K | Direct | Nov 18, 2019 (4d) |
| Feb 20, 2018 | GHDX | ↓ Sell | 4,942 | $32.84 | $162K | Direct | Feb 22, 2018 (2d) |
| Dec 19, 2017 | GHDX | ↓ Sell | 5,334 | $36.99 | $197K | Direct | Dec 20, 2017 (1d) |
| Jul 19, 2017 | GHDX | ↓ Sell | 3,174 | $33.57 | $107K | Direct | Jul 21, 2017 (2d) |
| Feb 16, 2017 | GHDX | ↓ Sell | 2,495 | $30.09 | $75K | Direct | Feb 17, 2017 (1d) |
| May 10, 2016 | GHDX | ↓ Sell | 6,324 | $27.20 | $172K | Direct | May 12, 2016 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other VCYT insiders
Open-market trades in the last 12 months
About Phillip G. Febbo's insider trades
Phillip G. Febbo is Chief Scientific & Med Officer at Veracyte (VCYT). Since May 10, 2016, Phillip has reported no open-market purchases and 16 sales worth $4.2M on SEC Form 4. In the last 12 months: 2 sales ($1.0M).
6 sales (41% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include shares withheld for taxes (23 filings), grants and awards (16 filings), option exercises (6 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VCYT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.